{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"194.61","value":"147.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Cycle 1, Day 1: 0.5-4 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.54","value":"217.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 1, Day 1: 6-10 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.48","value":"70.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Cycle 1, Day 15: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"203.07","value":"222.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Cycle 1, Day 15: 0.5-4 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"106.79","value":"310.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 1, Day 15: 6-10 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.95","value":"70.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Cycle 2, Day 1: Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received lenvatinib 14 mg/m\\^2, capsules, orally, once daily, plus ifosfamide 3000 mg/m\\^2/day, intravenously and etoposide 100 mg/m\\^2/day, intravenously. Ifosfamide and etoposide were administered on Days 1 to 3 of each 21-day cycle for up to 5 cycles. Lenvatinib was administered in continuous 21-day cycles. Treatment continued until PD, development of unacceptable toxicity, participant choice, withdrawal of consent or discontinuation of study by the sponsor, whichever occurred first.","id":"OG000","title":"Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide"}],"paramType":"MEAN","populationDescription":"Population Pharmacokinetic (PK) Analysis Set included those participants who received at least 1 dose of lenvatinib and had documented dose administration history and measurable plasma concentrations of lenvatinib. Here \"overall number of participants analyzed, N\" signifies participants who were evaluable for this outcome measure. Here \"number analyzed, n\" signifies participants who were evaluable for this outcome measure at given time points.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: Pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: Pre-dose (each Cycle length = 21 days)","title":"Treatment Arm A: Plasma Concentration of Lenvatinib","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}